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S226 Poster Session IResults: 18 patients withHLA-Ab against UCB unit 1 (9), UCB unit
2 (2) or both UCB units (7) were identified. No differences in cell
doses, viability or baseline characteristics were noted between
patients with/without HLA-Ab. The presence of HLA-Ab was asso-
ciated with an increased risk of graft failure (HLA-Ab against either
UCB unit: OR 8.67, 95%CI 1.89–39.68, p 5 0.0055; HLA-Ab
against both UCB units: OR 16.27, 2.82–93.87, p 5 0.0034). Neu-
trophil engraftment was delayed in the presence of HLA-Ab (median
21 vs. 29 days, p5 0.04) and fewer patients engrafted platelets in the
presence of HLA-Ab (76.4% vs. 50%, p 5 0.03). HLA-Ab against
UCB unit 1 was associated with UCB unit 2 dominance (OR 9.43,
95%CI 1.16–76.47, p 5 0.015), while HLA-Ab against UCB unit
2 was associated with a non-significant trend toward UCB unit 1
dominance (OR 2.70, 95%CI 0.63–12.5, p 5 0.28). Overall survival
was inferior in the presence of HLA-Ab against UCB unit 2 (p 5
0.044) or both UCB units (p5 0.027), but not with HLA-Ab against
UCB unit 1 only.
Conclusions: In DUBCT, the presence of HLA-Ab increases the
risk of graft rejection, prolongs time to engraftment, predicts UCB
dominance and is associated with inferior outcome.HLA-Ab screen-
ing should be incorporated into UCB unit selection strategies in
DUCBT.198
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Through an in vivo zebrafish screen for modulators of hematopoi-
etic stem cell (HSC) development, a small molecule, 16,16-dimethyl
prostaglandin E2 (FT1050) was identified (North, 2007). FT1050
was shown to enhance the engraftment potential of HSCs from mu-
rine bone marrow (mBM) or human umbilical cord blood (hCB) in
murine engraftment models through an increase in proliferation,
survival, migration and homing after a brief (1 to 2 hr) ex vivo treat-
ment (North, 2007; North, 2009; Hoggatt, 2009; North, Goessling,
Zon, unpublished data).We further optimized the ex vivo hCB incu-
bation protocol using whole genome expression arrays and deter-
mined that HSC-containing cell products should be incubated
with 10mMFT1050 for 2 hrs at 37C to obtain the optimal response.
In addition, we observed that FT1050 induces similar gene expres-
sion changes in hBM- and mobilized peripheral blood-derived
CD341 cells. Subsequent functional studies demonstrated that in
keeping with increases of up to 18-fold in CXCR4 gene expression,
cell surface CXCR4 protein expression was also significantly in-
creased. One hour after treatment with10mM FT1050 for 2 hrs at
37C, 4861.9% of CB CD341 cells expressed CXCR4 compared
to 3.560.01% in DMSO control (p\0.05). In vivo CFU-S12 anal-
ysis showed that treatment of mBM cells with 10mM FT1050 for 2
hrs at 37C resulted in greater proliferation with a statistically signif-
icant increase in colony formation, 11.561.4, compared to 460.8
colonies with DMSO control (p\ 0.001). This short-term ex vivo
incubation protocol, 10mM FT1050 for 2 hrs at 37C, has been in-
troduced into an ongoing Phase Ib clinical trial in adults with hema-
tologic malignancies receiving a nonmyeloablative conditioning
(melphalan, fludarabine and ATG) followed by double hCB trans-
plantation, in which one of the two hCBs is incubated with
FT1050 prior to infusion. The primary objective of the study is to
determine the safety of FT1050 treatment of hCB. Preliminary
data demonstrate that this ex vivo incubation can be reliably per-
formed at the clinical site on the day of infusion with good cell recov-
ery and viability. 11 subjects with a median age of 44 years have been
accrued to date, of which two have been treated using the optimized
ex vivo incubation protocol. 10 of 11 patients have achieved an ANC
. 500 beforeDay 42. Transplant relatedmortality has been lowwithone death at Day 53 from respiratory failure. 9 patients are alive, of
which 7 are disease-free. Accrual is ongoing.199
ALLOGENEIC TRANSPLANTATION USING HAPLOIDENTICAL DONOR VER-
SUS UNRELATED CORD BLOOD DONOR: A SINGLE CENTER RETROSPEC-
TIVE STUDY
Gonzalez-Vicent, M., Molina, B., Andion, M., Sevilla, J., Ramirez, M.,
Perez, A., Lassaletta, A., Diaz, M.A. Ni~no Jesus Childrens Hospital,
Madrid, Spain
We have performed a retrospective comparison of pediatric pa-
tients with leukemia receiving a haplo transplant (n 5 29) or
UCBT (n 5 38) in Ni~no Jesus Children’s Hospital since 1996 to
2010. There were not significant differences in immunophenotype,
disease status and antecedent of prior autograft. However, haplo re-
cipients tended to be older and of male gender.
Engraftment failure was significantly higher following UCBT
965% compared to 765% in haplo transplants (p5 0.001). Median
neutrophil engraftment were at 13 days for haplo and 20 days for
UCBT (p 5 0.01) and platelet engraftment at 11 days for haplo
and 56 days for UCBT (p 5 0.0001). Supportive care (transfusions,
antibiotics, parenteral nutrition and hospitalization days) were sig-
nificantly higher for cord blood transplants.
TRM and acute GVHD (more than grade II) incidence was higher
in UCBT compared to haplo transplants. There were not significant
differences in chronic GVHD and relapse probability between the
two groups. Results are summarized in table 1.
Disease-free survival (DFS) with a median follow-up of 16 months
(range: 1-42) and 57 months (range: 1-150) were of 44610% and
3267% (p 5 0.03) for haplo transplants and UCBT respectively.
When we analyzed AML, there were not differences in DFS with
both type of donor (p 5 0.6). However, DFS for ALL was better
with haplo (41613%) against cord blood (266 9%) (p 5 0.03). Ac-
cording to phase of disease, DFS was similar in early phase (p5 0.7),
but in advanced phase outcomewas better with haplo (37614%) ver-
sus cord blood (2168%) (p 5 0.05).
Multivariate analysis of DFS showed that the main prognostic fac-
tors were disease status at transplant (HR 2.49, p 5 0.02), chronic
GVHD (HR 0.21, p 5 0.0001) and source of stem cells (HR 5.75,
p 5 0.001).
In conclusion, our data suggest that haploidentical donor is a good
alternative for patients lacking an HLA identical donor.
Table 1. Results.
aGVHD >II TRM Relapse DFSHaplo (n529) 19±7% 25±9% 48±12% 44±10%
UCB (n538) 44±10% 57±9% 25±9% 32±7%
P 0.03 0.05 0.7 0.03200
CD341 STEM CELL SELECTION AND CD31 ADDBACK FOR PEDIATRIC
RECIPIENTS OF MATCHED UNRELATED ADULT DONOR (MUD) PERIPH-
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SYSTEMIC VIRAL INFECTIONS (SVI), AND INVASIVE FUNGAL INFECTIONS
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Background: CD341 stem cell selection depletes T cells responsi-
ble for severe aGVHD (Lang et al., Blood, 2003). CD341 selected
grafts have been associated with delayed IR (Ball et al, BMT, 2005,
Eyrich et al, BJH, 2001). Delayed IR is a significant risk factor for
Poster Session I S227severe opportunistic infections, a major cause of transplant related
mortality (Lang/ Handgretinger, BMT, 2008). We sought to deter-
mine engraftment, survival, IR, infection risk and frequency of
PTLD andGVHD in pediatrics recipients following CD34-selected
MUD PBSCT.
Methods:Pts# 30 yrs requiring aMUD transplant for selectivema-
lignant and nonmalignant disease who were eligible. HLA matching
included 8/10, 9/10 and 10/10 at intermediate resolutionHLAA and
B and high resolution HLA C, DRB1 and D2. Isolex 300i (Nexell,
Irvine, CA) immunomagnetic cell selection system was used for
CD34 selection with a goal of achieving $ 5 x106 CD34/kg
PBSC. T cells were added back to reach a total CD3 dose of
1.0-2.6x105/kg. GVHD prophylaxis consisted only of tacrolimus
(Bhatia/Cairo et al, BBMT, 2010). Supportive care was as we have
previously described (Bradley/Cairo, BMT, 2007).
Results: 19 pts, median f/u: 534d, median age: 15.3 yrs (10-23); 12:7
M:F, HLAmatch 26% 10/10, 31% 9/10, 42% 8/10; 68%malignant.
Infused grafts contained amedian of 1.6x105CD31/kg (0.1-4.8) and
5.1x106CD341/kg (2.0-13.3). Probabilities of neutrophil and plate-
let engraftment, grade II-IV aGVHD, cGVHD and day 100 TRM
were 100%, 82.3%, 15.8%, 24.2% and 0%, respectively. CD3,
CD4, CD8, CD19 and CD56 counts at day1180/365 reached nor-
mal in 11/30, 0/15, 22/46, 56/76 and 94/100% of patients, respec-
tively. IgG, IgM, and IgA reached normal in 47/50, 59/50, and 59/
33% of patients, respectively. One pt (5.2%) developed PTLD. 11
donor/pts were CMV positive, and 2 pts experienced CMV SVI.
The 1-yr probability of developing SVI and IFI was 42.3% and
28.0%, respectively. Despite the high incidence of SVI and IFI,
the 1-yr probability of mortality due to SVI and IFI was 5.3%
(CI95: 0-65%) and of OS was 84.2% (CI95: 59-95).
Conclusions: Rapid neutrophil engraftment, low rate of PTLD,
aGVHD/ cGVHD, and low day 100 TRMwere observed. Although
immune reconstitution was not mature at 1 yr post transplant, the
overall probability of infection related mortality was relatively low.
These results support continued investigation of CD34-selected
MUD PBSCT in selective pediatric AlloSCT recipients.201
HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MINORITIES
Ciurea, S.O., Saliba, R.M., Rondon, G., Sharma, M., Montes, N.,
Bosque, D., McMannis, J., Fernandez-Vina, M., Xie, S.,
Konopleva, M., Parmar, S., Nieto, Y., Kebriaei, P., Quazilbash, M.,
Alousi, A., Popat, U., Hosing, C.M., Shpall, E.J., Khouri, I.F., de
Lima, M., Champlin, R.E. The University of TexasMDAnderson Cancer
Center, Houston, TX
Hematopoietic stem cell transplants have been performed mostly
from matched related or unrelated donors (MUD). Given the racial
composition of the unrelated donor registries, it has been difficult
to identify a MUD for non-Caucasian patients (pts). A review of all
the MUD pts transplanted at MD Anderson (MDACC) past 25
years revealed that of 2117 pts, 1677 (79.2%) were whites (W),
271 pts (12.8%) Hispanics (H), 109 (5%) Afican-Americans (AA)
and 33 (1.5%) were Asians (A). Similar racial distribution was noted
with pts receiving a 9/10 MUD during the same period of time.
We hypothesized that haploidentical stem cell transplantation
(HaploSCT) would be an alternative for the minorities without
a matched donor and treated 24 consecutive pts with a conditioning
regimen consisting of fludarabine (40mg/m2/day  4), melphalan
(140mg/m2) and thiotepa (10mg/kg). 4 pts . 55 years/comorbid-
ities received a RIC with fludarabine and lower doses of melphalan
(100mg/m2) and thiotepa (5mg/kg). GVHD prophylaxis consisted
of post transplant cyclophosphamide (50mg/kg/day  2), tacroli-
mus and mycophenolate.
Results: Racial distribution in this group was 8/24 (33.3%) W, 6/
24 (25%) H, 5/24 (21%) AA, 4/24 (16.6%) A, 1/24 (4%) other, for
a total of 66.6% minority population. Median age was 47 years (24-
65). All pts but one received bone marrow stem cells. 4 pts had
prior allogeneic transplants. 13 pts had AML/MDS (8 poor-risk cy-
togenetics), 6 pts had CML/MPD (5/5 blast phase CML), 5 pts had
lymphoma/CLL. Donor-recipient HLA matching was: 5/10 in 12
pts (50%), 6/10 in 3/25 pts (12%), 7/10 in 5/25 pts (20%) and 8/
10 in 4/25 (16%). 10 pts (42%) were in remission at the time of
transplant. All 23 evaluable pts (one had early death) engraftedwith 100% donor chimerism (100% engraftment) after a median
of 19 days (5-40). Cumulative incidence of day-100 treatment-re-
lated mortality (TRM) was 14%. No patients less than 50 years
died of TRM. Grade II-IV aGVHD occurred in 4 patients and
cGVHD in 1 patient. 7/18 (39%) pts relapsed while only 1 for
the pts in remission at the time of transplant. After a median fol-
low-up of 6 months (range 3-18) for survivors of . 100 days
(N 5 14), OS for the whole group was 80%, while PFS for pts
in remission at the time of transplant was 89% (N 5 10, CI
43-98%). No differences in OS/PFS were noted between the
Caucasian and non-Caucasian population.
Conclusion: HaploSCT is a feasible and safe transplant alternative
for minority pts who lack a matched donor.202
HLA-HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION USING DEPLETION OF CD36CD19 IN CHILDREN
AND ADOLESCENTS: EXPERIENCE AT A SINGLE INSTITUTION
Im, H.J., Park, M., Koh, K.N., Kim, B.E., Choi, E.S., Seo, J.J. Asan
Medical Center Children’s Hospital, Seoul, Republic of Korea
Objective:Toevaluate the safety and efficacy of haploidenticalHCT
(h-HCT) with T-cell depleted graft in children and adolescents
Patients and methods: Between July 2008 and April 2010, 11 pa-
tients received allogeneic PBSCT from mismatched family donors.
Of 11 patients, 6 had SAA (5 acquired, 1 Fanconi anemia), and
5 had hematologic malignancy (HM), of which 3 were AML (1
CR2, 1 refractory, 1 graft failure after CBT), 1 was ALL in CR3,
and 1 was MDS-RA. A total of 13 h-HSCTs were performed in
11 patients. All 13 cases were conditioned with non-myeloablative
regimen containing fludarabine, and busulfan at a dose of 8mg/kg
was added for hematologic malignancies. ATG was also included
except for cases of graft failure and none of enrolled patients re-
ceived any kind of irradiation. The mobilized and collected product
was processed for CD3 alone or CD3/CD19 depletion using
CliniMACS.
Results:Of 11 patients, 9 achieved neutrophil engraftment at a me-
dian of 11 days of whom 2 experienced late graft failure (GF) on
day 125 and 1200, respectively. Four patients developed acute
GVHD of grade II and none had . II aGVHD. Of 4 patients
who experienced GF (2 primary and 2 late), 2 received the 2nd
h-HCT from different donors and all 2 are alive with complete do-
nor chimerism. At a median follow-up of 12.2 (5.927.7) months,
all 11 patients are alive. Of 6 patients with SAA, 4 are well and alive
in a complete donor chimerism without transfusion (TF) need, 1
remains on infrequent need of TF with 95% donor chimerism at
day 1221, and 1 received a 2nd h-HCT for primary GF, after
which the patient remains on infrequent need of TF with full donor
chimerism at day 1145. Of 5 patients with HM, 3 patients with
AML are alive in CR at days 1178, 1412, and 1812, respectively,
although 1 of those experienced late graft failure. The remaining 2
patients are alive with disease at days 1334 and 1377, respectively,
of whom 1 with MDS experienced 1 GF and the other with ALL
relapsed at day 1269. Although no infection-related death
occurred, most of the patients had a viral reactivation or disease, in-
cluding PTLD and CMV retinitis.
Conclusions:TheHCT using haploidentical family donors is a fea-
sible option for children with diseases curable with HCT, but lack
a suitable related or unrelated donor. However, graft failure and in-
fection are still obstacles to overcome to improve the outcome of
hHCT in children and adolescents.203
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